Brief: Nicox Initiates First Phase 3 Trial Of NCX 470 In Glaucoma

Nicox SA

02/06/2020 06:37

June 2 (Reuters) - Nicox SA  NCOX.PA :
    * INITIATES FIRST PHASE 3 TRIAL OF NCX 470 IN GLAUCOMA
    * NCX 470 WILL COMPETE IN >$6 BILLION WORLDWIDE GLAUCOMA
MARKET
    * ADAPTIVE DOSE SELECTION IN MONT BLANC ALLOWS START OF
SECOND
PHASE 3 TRIAL, DENALI
    * MONT BLANC CLINICAL TRIAL TO RANDOMIZE 600+ PATIENTS AT
SITES
PRIMARILY ACROSS U.S
    * COMPANY IS NOT CURRENTLY PROVIDING A TARGET DATE FOR MONT
BLANC
TOPLINE RESULTS
    * WE CURRENTLY DO NOT ANTICIPATE DELAYS TO OUR CLINICAL
TIMELINES

Source text for Eikon:  ID:nGNE4rsTMn 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))